HomeCompareIMMPF vs RYLD

IMMPF vs RYLD: Dividend Comparison 2026

IMMPF yields 3529.41% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMMPF wins by $2151927237632.54M in total portfolio value
10 years
IMMPF
IMMPF
● Live price
3529.41%
Share price
$0.09
Annual div
$3.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2151927237632.58M
Annual income
$2,038,319,550,631,819,300.00
Full IMMPF calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — IMMPF vs RYLD

📍 IMMPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMMPFRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMMPF + RYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMMPF pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMMPF
Annual income on $10K today (after 15% tax)
$300,000.00/yr
After 10yr DRIP, annual income (after tax)
$1,732,571,618,037,046,300.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, IMMPF beats the other by $1,732,571,618,037,044,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMMPF + RYLD for your $10,000?

IMMPF: 50%RYLD: 50%
100% RYLD50/50100% IMMPF
Portfolio after 10yr
$1075963618816.31M
Annual income
$1,019,159,775,315,910,900.00/yr
Blended yield
94.72%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMMPF buys
0
RYLD buys
0
No recent congressional trades found for IMMPF or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMMPFRYLD
Forward yield3529.41%12.14%
Annual dividend / share$3.00$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$2151927237632.58M$44.5K
Annual income after 10y$2,038,319,550,631,819,300.00$2,587.35
Total dividends collected$2144135504039.73M$18.8K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: IMMPF vs RYLD ($10,000, DRIP)

YearIMMPF PortfolioIMMPF Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$363,641$352,941.18$11,914$1,213.65+$351.7KIMMPF
2$12,383,857$11,994,761.18$14,099$1,351.30+$12.37MIMMPF
3$395,010,981$381,760,253.60$16,580$1,494.55+$394.99MIMMPF
4$11,803,130,868$11,380,469,118.13$19,384$1,642.61+$11803.11MIMMPF
5$330,437,068,596$317,807,718,567.85$22,535$1,794.70+$330437.05MIMMPF
6$8,668,758,125,687$8,315,190,462,289.50$26,063$1,950.00+$8668758.10MIMMPF
7$213,147,085,330,887$203,871,514,136,401.38$29,995$2,107.69+$213147085.30MIMMPF
8$4,912,912,994,478,026$4,684,845,613,173,977.00$34,361$2,266.99+$4912912994.44MIMMPF
9$106,175,408,411,930,130$100,918,591,507,838,660.00$39,194$2,427.12+$106175408411.89MIMMPF
10$2,151,927,237,632,584,700$2,038,319,550,631,819,300.00$44,525$2,587.35+$2151927237632.54MIMMPF

IMMPF vs RYLD: Complete Analysis 2026

IMMPFStock

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

Full IMMPF Calculator →

RYLDETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this IMMPF vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMMPF vs SCHDIMMPF vs JEPIIMMPF vs OIMMPF vs KOIMMPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.